PTC Therapeutics, Inc. (PTCT) FY2026 YTD Q3 Statement of Cash Flows

Published Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)

2026-01-01 to 2026-09-30

Statement of Cash Flows

Swipe to see the full flow
PTC Therapeutics, Inc. cash flow reconciliation, Jan 1, 2026 through Sep 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Orange marks positive customer-advance and deferred-revenue changes that add to operating cash in the reconciliation. These are net changes, not gross customer receipts. Negative changes are neutral reconciliation adjustments; they do not by themselves identify cash payments. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net (loss) income attributable to common stockholders → Net cash from operating activities: $28,994,000.00Non-cash interest expense on liability related to sale of future royalties → Operating adjustments reconciliation: $196,861,000.00Share-based compensation expense → Operating adjustments reconciliation: $70,539,000.00Depreciation and amortization → Operating adjustments reconciliation: $48,104,000.00Loss on extinguishment of debt → Operating adjustments reconciliation: $19,263,000.00Non-cash operating lease expense → Operating adjustments reconciliation: $5,358,000.00Prepaid expenses and other current assets → Operating adjustments reconciliation: $4,858,000.00Inducement expense related to repurchase of 2026 Convertible Notes → Operating adjustments reconciliation: $3,386,000.00Amortization of debt issuance costs → Operating adjustments reconciliation: $1,459,000.00Tangible asset impairment and losses on transactions, net → Operating adjustments reconciliation: $927,000.00Unrealized foreign currency transaction losses, net → Operating adjustments reconciliation: $637,000.00Deferred revenue → Operating adjustments reconciliation: $7,000.00Operating adjustments reconciliation → Net cash from operating activities: $15,766,000.00Operating adjustments reconciliation → Non-cash royalty revenue related to sale of future royalties: $199,624,000.00Operating adjustments reconciliation → Trade and royalty receivables, net: $60,076,000.00Operating adjustments reconciliation → Inventory, net: $31,332,000.00Operating adjustments reconciliation → Accounts payable and accrued expenses: $20,521,000.00Operating adjustments reconciliation → Amortization of discounts on investments, net: $13,600,000.00Operating adjustments reconciliation → Other liabilities: $6,827,000.00Operating adjustments reconciliation → Unrealized gain on marketable securities - equity investments: $3,018,000.00Operating adjustments reconciliation → Deposits and other assets: $635,000.00Proceeds from issuance of 2031 Convertible Notes → financing reconciliation: $550,000,000.00Proceeds from exercise of options → financing reconciliation: $24,986,000.00Proceeds from employee stock purchase plan → financing reconciliation: $3,163,000.00financing reconciliation → Net cash from financing activities: $145,045,000.00financing reconciliation → Repurchase of the 2026 Convertible Notes: $402,653,000.00financing reconciliation → Debt issuance costs related to 2031 Convertible Notes: $14,572,000.00financing reconciliation → Conversion of the 2026 Convertible Notes: $12,879,000.00financing reconciliation → Payments on finance lease principal: $3,000,000.00Sale of marketable securities- available for sale → investing reconciliation: $1,029,918,000.00Sale of marketable securities- equity investments → investing reconciliation: $39,655,000.00investing reconciliation → Purchases of marketable securities- available for sale: $1,674,893,000.00investing reconciliation → Purchases of marketable securities- equity investments: $38,864,000.00investing reconciliation → Acquisition of product rights and licenses: $8,474,000.00investing reconciliation → Purchases of fixed assets: $6,046,000.00Net cash used in investing activities → investing reconciliation: $658,704,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $998,334,000.00Net cash from operating activities → Cash sources and uses: $44,760,000.00Net cash from financing activities → Cash sources and uses: $145,045,000.00Cash sources and uses → Exchange-rate effect: $4,100,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $525,335,000.00Cash sources and uses → Net cash used in investing activities: $658,704,000.00Net (loss) income attributable to common stockholders: $28,994,000.00Net (loss) income attributable to commonstockholders+$28.99 MDepreciation and amortization: $48,104,000.00Depreciation & amortization+$48.10 MTangible asset impairment and losses on transactions, net: $927,000.00Tangible asset impairment and losses ontransactions, net+$927.00 KNon-cash operating lease expense: $5,358,000.00Operating lease amortization+$5.36 MNon-cash royalty revenue related to sale of future royalties: -$199,624,000.00Non-cash royalty revenue related to sale of futureroyalties−$199.62 MNon-cash interest expense on liability related to sale of future royalties: $196,861,000.00Non-cash interest expense on liability related to saleof future royalties+$196.86 MUnrealized gain on marketable securities - equity investments: -$3,018,000.00Unrealized equity gain & loss−$3.02 MLoss on extinguishment of debt: $19,263,000.00Debt extinguishment gain & loss+$19.26 MAmortization of discounts on investments, net: -$13,600,000.00Investment discount & premium−$13.60 MAmortization of debt issuance costs: $1,459,000.00Debt issuance cost amortization+$1.46 MShare-based compensation expense: $70,539,000.00Stock-based compensation+$70.54 MUnrealized foreign currency transaction losses, net: $637,000.00Unrealized FX gain & loss+$637.00 KInventory, net: -$31,332,000.00Inventories−$31.33 MPrepaid expenses and other current assets: $4,858,000.00Prepaid & other assets+$4.86 MTrade and royalty receivables, net: -$60,076,000.00Receivables, net−$60.08 MDeposits and other assets: -$635,000.00Deposits & other assets−$635.00 KAccounts payable and accrued expenses: -$20,521,000.00Payables & accrued liabilities−$20.52 MOther liabilities: -$6,827,000.00Other operating liabilities−$6.83 MInducement expense related to repurchase of 2026 Convertible Notes: $3,386,000.00Inducement expense related to repurchase of 2026Convertible Notes+$3.39 MDeferred revenue: $7,000.00Deferred revenue+$7.00 KNet cash from operating activities: $44,760,000.00Operating cash+$44.76 MOperating adjustments reconciliation: $351,399,000.00Proceeds from exercise of options: $24,986,000.00Stock option exercises+$24.99 MProceeds from employee stock purchase plan: $3,163,000.00Stock plan proceeds+$3.16 MRepurchase of the 2026 Convertible Notes: -$402,653,000.00Repurchase of the 2026 Convertible Notes−$402.65 MPayments on finance lease principal: -$3,000,000.00Finance lease payments−$3.00 MProceeds from issuance of 2031 Convertible Notes: $550,000,000.00Convertible debt issued+$550.00 MDebt issuance costs related to 2031 Convertible Notes: -$14,572,000.00Debt issuance costs−$14.57 MConversion of the 2026 Convertible Notes: -$12,879,000.00Conversion of the 2026 Convertible Notes−$12.88 MNet cash from financing activities: $145,045,000.00Financing cash+$145.05 Mfinancing reconciliation: $578,149,000.00Purchases of fixed assets: -$6,046,000.00PP&E purchases−$6.05 MPurchases of marketable securities- available for sale: -$1,674,893,000.00AFS securities purchases−$1.67 BPurchases of marketable securities- equity investments: -$38,864,000.00Marketable securities purchases−$38.86 MSale of marketable securities- available for sale: $1,029,918,000.00AFS securities sales+$1.03 BSale of marketable securities- equity investments: $39,655,000.00Marketable securities proceeds+$39.66 MAcquisition of product rights and licenses: -$8,474,000.00Intangible asset purchases−$8.47 MNet cash used in investing activities: -$658,704,000.00. Cash required to fund net payments.Investing cash−$658.70 Minvesting reconciliation: $1,728,277,000.00Cash sources and uses: $1,188,139,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $998,334,000.00Beginning cash$998.33 MEnding cash: Cash, cash equivalents, and restricted cash: $525,335,000.00Ending cash$525.34 MExchange-rate effect: -$4,100,000.00FX effect−$4.10 MCASH RECONCILIATIONOperatingflowsFinancingflowsInvestingflowsFree cash flow$38.71 MOperating cash − cash spent on PP&ECash flow / Net income1.54×Operating cash flow ÷ net incomeNet cash change−$473.00 MEnding cash − beginning cash
Chart details

PTC Therapeutics, Inc. cash flow reconciliation, Jan 1, 2026 through Sep 30, 2026

Cash flows for Jan 1, 2026 through Sep 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Sep 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2025
998,334,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
44,760,000 US dollars. Net cash provided.
Net (loss) income attributable to common stockholders
28,994,000 US dollars
Depreciation and amortization
48,104,000 US dollars
Tangible asset impairment and losses on transactions, net
927,000 US dollars
Non-cash operating lease expense
5,358,000 US dollars
Non-cash royalty revenue related to sale of future royalties
negative 199,624,000 US dollars
Non-cash interest expense on liability related to sale of future royalties
196,861,000 US dollars
Unrealized gain on marketable securities - equity investments
negative 3,018,000 US dollars
Loss on extinguishment of debt
19,263,000 US dollars
Amortization of discounts on investments, net
negative 13,600,000 US dollars
Amortization of debt issuance costs
1,459,000 US dollars
Share-based compensation expense
70,539,000 US dollars
Unrealized foreign currency transaction losses, net
637,000 US dollars
Inventory, net
negative 31,332,000 US dollars
Prepaid expenses and other current assets
4,858,000 US dollars
Trade and royalty receivables, net
negative 60,076,000 US dollars
Deposits and other assets
negative 635,000 US dollars
Accounts payable and accrued expenses
negative 20,521,000 US dollars
Other liabilities
negative 6,827,000 US dollars
Inducement expense related to repurchase of 2026 Convertible Notes
3,386,000 US dollars
Deferred revenue
7,000 US dollars
Investing activities
negative 658,704,000 US dollars. Net cash used.
Purchases of fixed assets
negative 6,046,000 US dollars
Purchases of marketable securities- available for sale
negative 1,674,893,000 US dollars
Purchases of marketable securities- equity investments
negative 38,864,000 US dollars
Sale of marketable securities- available for sale
1,029,918,000 US dollars
Sale of marketable securities- equity investments
39,655,000 US dollars
Acquisition of product rights and licenses
negative 8,474,000 US dollars
Financing activities
145,045,000 US dollars. Net cash provided.
Proceeds from exercise of options
24,986,000 US dollars
Proceeds from employee stock purchase plan
3,163,000 US dollars
Repurchase of the 2026 Convertible Notes
negative 402,653,000 US dollars
Payments on finance lease principal
negative 3,000,000 US dollars
Proceeds from issuance of 2031 Convertible Notes
550,000,000 US dollars
Debt issuance costs related to 2031 Convertible Notes
negative 14,572,000 US dollars
Conversion of the 2026 Convertible Notes
negative 12,879,000 US dollars
Operating adjustment reconciliation
351,399,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
578,149,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
1,728,277,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
negative 4,100,000 US dollars
Ending cash on Sep 30, 2026
525,335,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
1,188,139,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 472,999,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
1.54×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
44,760,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
6,046,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
38,714,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income enters operating cash directly in the reconciliation. The adjustment junction contributes the remaining $15.77M after reconciling the other positive and negative adjustments. These connections depict an accounting reconciliation, not traced cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 44,760,000 US dollars minus 6,046,000 US dollars equals 38,714,000 US dollars.
PTC Therapeutics, Inc. (PTCT) FY2026 YTD Q3 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!